Noninvasive Diagnostic Strategies for Membranous Nephropathy in the Nephrotic Syndrome Study Network
Clinical Journal of the American Society of Nephrology · 2025-05 · 20 (5) · 697-705
DOI: 10.2215/cjn.0000000671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 28.02.2025. Verfasst von Jarcy Zee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Key Points Antiphospholipase A2 receptor antibody seropositivity by ELISA ≥2 and positive indirect immunofluorescence was optimal. Noninvasive diagnosis of phospholipase A2 receptor–associated membranous nephropathy among patients with proteinuria is feasible using both assays.
Background
Clinical practice guidelines recommend that a kidney biopsy is no longer required to confirm a diagnosis of membranous nephropathy (MN) in patients with nephrotic syndrome and a positive test for antiphospholipase A2 receptor antibodies (PLA2R-Ab). However, the optimal diagnostic strategy for using the PLA2R-Ab ELISA, PLA2R-Ab indirect immunofluorescence (IIF) test, and genetic risk score (GRS) for diagnosing MN, including the tests' optimal thresholds for positivity among incident patients with proteinuria, is still unknown.
Methods
We used serum samples at or before the first clinically indicated kidney biopsy from participants in the Nephrotic Syndrome Study Network to analyze test performance characteristics using different combinations and cutoffs of the PLA2R-Ab ELISA, IIF, and GRS for diagnosing MN. Secondary analyses included serum samples within 6 months after biopsy but before any immunosuppression use.
Results
There were 325 study participants with serum samples available on or before the day of kidney biopsy and an additional 143 study participants with samples within 6 months after biopsy but before any immunosuppression use. Of these participants, 26% ( n =85) had biopsy-confirmed MN. The combination of ELISA ≥2 RU/ml and positive IIF was the optimal approach, with sensitivity of 0.60, specificity of 1.00, negative predictive value of 0.92, and positive predictive value of 1.00. Using IIF to confirm only borderline ELISA titers between 2 and 20 RU/ml resulted in similar sensitivity but specificity of >0.99. In our multiethnic study sample, we did not find improved diagnostic performance with the addition of GRSs.
Conclusions
In the Nephrotic Syndrome Study Network cohort, combined PLA2R-Ab testing with ELISA and IIF provided optimal test characteristics in making a noninvasive diagnosis of MN before or soon after kidney biopsy, including in patients with subnephrotic proteinuria. Further studies in multiethnic populations are needed to assess whether genetic data can augment this approach.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
- Division of Nephrology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Cabaletta Bio, Philadelphia, Pennsylvania.
- Division of Nephrology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.
- Division of Nephrology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
ORCID-Profile: Jarcy Zee, Ahmed Abdullah, Lili Liu, Krzysztof Kiryluk, Laurence H Beck
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Zee, J., Hogan, J. J., Abdullah, A., Liu, L., Kiryluk, K., & Beck, L. H. (2025). Noninvasive Diagnostic Strategies for Membranous Nephropathy in the Nephrotic Syndrome Study Network. Clinical Journal of the American Society of Nephrology, 20(5), 697-705. https://doi.org/10.2215/cjn.0000000671
Vancouver
Zee J, Hogan JJ, Abdullah A, Liu L, Kiryluk K, Beck LH. Noninvasive Diagnostic Strategies for Membranous Nephropathy in the Nephrotic Syndrome Study Network. Clinical Journal of the American Society of Nephrology. 2025;20(5):697-705. doi:10.2215/cjn.0000000671
BibTeX
@article{Zee2025,
author = {Zee, Jarcy and Hogan, Jonathan J and Abdullah, Ahmed and Liu, Lili and Kiryluk, Krzysztof and Beck, Laurence H},
title = {Noninvasive Diagnostic Strategies for Membranous Nephropathy in the Nephrotic Syndrome Study Network},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2025},
volume = {20},
number = {5},
pages = {697--705},
doi = {10.2215/cjn.0000000671}
}
EUVIMED